Company Overview and News

0
Ready for F-35s: Runway Resurfaced at RAF Marham

2018-06-05 asdnews
Preparations for the arrival of the UK’s new F-35 multi-role combat aircraft have taken a major step forward with the completion of resurfacing work on the secondary runway at RAF Marham.
GALLF GLLRY GFRD

0
Galliford Try warns bad weather will add to cost of Aberdeen road project

2018-05-22 telegraph.co.uk
Construction and housing company Galliford Try is facing higher bills to build Aberdeen’s troubled ring road after bad weather caused delays.
BBYB GALLF BBY BAFYY GLLRY BAFBF GFRD

4
UPDATE 1-UK Stocks-Factors to watch on May 22

2018-05-22 reuters
May 22 (Reuters) - Britain’s FTSE 100 index is seen opening down 4 points on Tuesday, according to financial bookmakers with futures down 0.05 percent ahead of the cash market open.
CRWCY NG GALLF NAWI BMY NEXGY CEBA 84HW POBA NANW GLLRY CEBB ICP CWK 86HW 85HW NGGTF NABB TLW BMBYF NGG GFRD

14
Is First Trust Dow Jones Global Select Dividend Index Fund (FGD) a Hot ETF Right Now?

2018-05-08 zacks
The First Trust Dow Jones Global Select Dividend Index Fund (FGD - Free Report) made its debut on 11/21/2007, and is a smart beta exchange traded fund that provides broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
ACWI FGD VT GES GALLF CTL GLLRY GFRD

28
ETF Month No. 8: Is IDV A Good International Dividend ETF?

2018-03-28 seekingalpha
I still prefer IQDE over IDV, but the usual warnings about low AUM and volume apply.
MQBKY NTRSP GALLF RDSB RDSA VTKLY HSB NTRS SVKAF VTKLF HSBC.PRA RYDAF MQG AZIHF HSBC ZFSVF GFRD HBCYF HCS.PRB RDS.B RDS.A AZIHY MCQEF HCS GLLRY 0303 0005 IDV ZURVY RYDBF HSEA HSEB IQDE

21
UPDATE 1-UK Stocks-Factors to watch on March 27

2018-03-27 reuters
March 27 (Reuters) - Britain’s FTSE 100 index is seen opening 78 points higher at 6,966 on Tuesday, according to financial bookmakers, with futures up 1.4 percent ahead of the cash market open.
HFD HLFDF RDS.B RDS.A DSITF GALLF RDSB DXCPY RDSA GLLRY HLFDY UUGRY RYDBF DC RYDAF UU GFRD UUGWF

0
Galliford Try to raise 158 mln stg to cover Carillion project costs

2018-03-27 reuters
LONDON, March 27 (Reuters) - British construction group Galliford Try said it would raise around 158 million pounds ($225 million) through a fully underwritten rights issue to cover the costs of a troubled project it had been working on with the now-defunct Carillion.
BBYB GALLF BBY BAFYY GLLRY BAFBF GFRD

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...